Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

NCT04720131 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer
Anti-PD-1 Therapy
Targeted Molecular Therapy
Capecitabine

Interventions

DRUG: Camrelizumab
DRUG: apatinib
DRUG: Capecitabine

Sponsor

Beijing Friendship Hospital